Biography

Dr. Jessica McAlpine was born and raised in Vancouver. She did her medical training in the US, returning in 2006 to take a position at UBC and the BC Cancer Agency. She currently splits her time equally between clinical/surgical duties and translational research. She is part of the OVCARE research team (British Columbia’s Ovarian Cancer Research group) and Director of the OVCARE Tissue Bank. Her research focuses on specific subtypes of ovarian and endometrial cancers, and prevention.

Publications

McAlpine JN, Leung SC, Cheng A, Miller D, Talhouk A, Gilks CB, Karnezis AN. Human papillomavirus (HPV)independent vulvar squamous cell carcinoma has a worse prognosis than HPVassociated disease: a retrospective cohort study. Histopathology. 2017 Aug;71(2):238-246. PMID 28257152

Cochrane DR, Tessier-Cloutier B, Lawrence KM, Nazeran T, Karnezis AN, Salamanca C, Cheng AS, McAlpine JN, Hoang LN, Gilks CB, Huntsman DG. Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin? J Pathol. 2017 Jul 5. [Epub ahead of print] PMID: 28678427

Proctor L, Pradhan M, Leung S, Cheng A, Lee CH, Soslow RA, Gilks CB, Talhouk A, McAlpine JN, Danielsen HE, Hoang LN. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer. Gynecologic Oncology. 2017 Jun 21. [Epub ahead of print]  PMID: 28647100

Wang YK, Bashashati A, Anglesio MS, Cochrane DR, Grewal DS, Ha G, McPherson A, Horlings HM, Senz J, Prentice LM, Karnezis AN, Lai D, Aniba MR, Zhang AW, Shumansky K, Siu C, Wan A, McConechy MK, Li-Chang H, Tone A, Provencher D, de Ladurantaye M, Fleury H, Okamoto A, Yanagida S, Yanaihara N, Saito M, Mungall AJ, Moore R, Marra MA, Gilks CB, Mes-Masson AM, McAlpine JN, Aparicio S, Huntsman DG, Shah SP. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. Nat Genet. 2017 Jun;49(6):856-865. PMID: 28436987

Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, … McAlpine JN, … Gayther SA, Antoniou AC, Pharoah PDP. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May;49(5):680-691. PMID: 28346442

Hanley GE, McAlpine JN, Pearce CL, Miller D. The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States. Am J Obstet Gynecol. 2017 Mar;216(3):270.e1-270.e9. PMID: 27810554

McAlpine JN, Kim R. Akbari A, Eshraugh S, Knebel, K, Prigge E, Jordan S, Singh N, Miller DM, Reuschenbach M, Gilks CB. HPV-independent differentiated vulvar intraepithelial neoplasia (dVIN) is associated with an aggressive clinical course. International Journal of Gynecological Pathology. Int J Gynecol Pathol. 2017 Mar 17. [Epub ahead of print] PMID: 28319571

Karnezis AN, Leung S, Cheng A, Miller D, Talhouk A, Gilks CB, McAlpine JN. HPV-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study. Laboratory Investigation. 2017 Feb; 97: 293A-293A. PMID: 28257152

Hoang LN, Kinloch MA, Leo JM, Grondin K, Lee CH, Ewanowich C, Kobel M, Cheng A, Talhouk A, McConechy M, Huntsman DG, McAlpine JN, Soslow RA, Gilks CB. Interobserver agreement in endometrial carcinoma histotype diagnosis varies depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. Am J Surg Pathol. 2017 Feb;41(2):245-252. PMID: 28079598

Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017 Jan 6:123(5); 802-813. PMID: 28061006

Talhouk A, McAlpine JN. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncolo Res Pract. 2016 Dec 13;3:14. PMID: 27999680

Schlosser C, Bodenschatz N, Lam S, Lee M, McAlpine JN, Miller DM, Van Niekerk DJ, Follen M, Guillaud M, MacAulay CE, Lane PM. Fluorescence confocal endomicroscopy of the cervix: pilot study on the potential and limitations for clinical implementation. J Biomed Opt. 2016 Dec 1;21(12):126011. PMID: 27999860

Färkkilä A, McConechy MK, Yang W, Talhouk A, Ng Y, Lum A, Morin RD, Bushell K, Riska A, McAlpine JN, Gilks CB, Unkila-Kallio L, Anttonen M, Huntsman DG. FOXL2 402C>G Mutation can be identified in the circulating tumor DNA of patients with adult-type granulosa cell tumor. J Mol Diagn. 2017 Jan;19(1):126-136. PMID: 27810330

Fujiwara K, McAlpine JN, Lheureux S, Matsumura N, Oza AM. Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. Am Soc Clin Oncol Educ Book. 2016;35:e247-57

Talhouk A, Hoang LN, McConechy MK, Nakonechny Q, Leo J, Cheng A, Leung S, Yang W, Lum A, Kobel M, Lee CH, Soslow RA, Huntsman DG, Gilks CB, McAlpine JN. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment. Gynecol Oncol. 2016 Oct;143(1):46-53. PMID: 27421752

McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: not your grandmother’s cancer. Cancer. 2016 Sep 15;122(18):2787-98. PMID: 27308732

Cheng AS, Karnezis AN, Jordan S, Singh N, McAlpine JN, Gilks CB. p16 Immunostaining allows for accurate subclassification of vulvar squamous cell carcinoma into HPV-associated and HPV-independent cases. Int J Gynecol Pathol. 2016 Jul 1;35(4):385-93. PMID: 26630231

McPherson A, Roth A, Laks E, Masud T, Bashashati A, Zhang AW, Ha G, Biele J, Yap D, Wan A, Prentice LM, Khattra J, Smith MA, Nielsen CB, Mullaly SC, Kalloger S, Karnezis A, Shumansky K, Siu C, Rosner J, Chan HL, Ho J, Melnyk N, Senz J, Yang W, Moore R, Mungall AJ, Marra MA, Bouchard-Cote A, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat Genet. 2016 Jul;48(7):758-67. PMID: 27182968

Roth A, McPherson A, Laks E, Biele J, Yap D, Wan A, Smith MA, Nielsen CB, McAlpine JN, Aparicio S. Bouchard-Cote A, Shah SP. Clonal genotype and population structure inference from single-cell tumor sequencing. Nat Methods. 2016 Jul:13(7);573-6. PMID: 27183439

McConechy MK, Talhouk A, Leung S, Chiu D, Yang W, Senz J, Reha-Krantz LJ, Lee CH, Huntsman DG, Gilks CB, McAlpine JN. Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. Clin Cancer Res. 2016 Jun 15;22(12):2865-73. PMID: 26763250

Kobel M, Atenafu EG, Rambau PF, Ferguson SE, Nelson GS, Ho TC, Panzarella T, McAlpine JN, Gilks CB, Clarke BA, Bernardini MQ. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. Gynecol Oncol. 2016 Jun;141(3):559-63. PMID: 27072807

Bodenschatz N, Lam S, Carraro A, Korbelik J, Miller DM, McAlpine JN, Lee M, Kienle A, MacAulay C. Diffuse optical microscopy for quantification of depth-dependent epithelial backscattering in the cervix. J Biomed Opt. 2016 Jun 1;21(6):66001. PMID: 27251077

McAlpine JN, Tone AA, Hanley GE. Opportunistic salpingectomy: we chose to act, not wait. J Obstet Gynaecol Can. 2016 May;38(5):425-7. PMID: 27261215

Bakhsh S, Kinloch M, Hoang LN, Soslow RA, Kobel M, Lee CH, McAlpine JN, McConechy MK, Gilks CB. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy. Histopathology. 2016 May;68(6):916-24. PMID: 26416160

Bernardini MQ, Gien LT, Lau S, Altman AD, Gilks B, Ferguson, SE, Kobel M, Soumelian V, Wesa M, Cameron, A, Nelson G, Han G, Clarke B, Ho TC, Panzarella T, Atenafu, EG, McAlpine JN. Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). Gynecol Oncol. 2016 Apr 30;141(1):148-54. PMID: 26854651

Healy CF, Pang E, Bakhsh S, White L, McAlpine JN, Yee WC, Harris AC. Subpubic cartilaginous cyst: a rare sub-clitoral mass. J Obstet Gynaecol Can. 2016 Feb;38(2):102-3. PMID: 27032732

Karnezis AN, Hoang LN, Coatham M, Ravn S, Almadani N, Tessier-Cloutier B, Irving J, Meng B, Li X, Chow C, McAlpine J, Kuo K-T, Mao T-L, Djordjevic B, Soslow RA, Huntsman DG, Gilks CB, Kobel M, Le CH. Loss of switch/sucrose non-fermenting complex protein expression associated with dedifferentiation in endometrial carcinomas. Mod Pathol. 2016 Jan 08;29:302-14. PMID: 26743474

Fujiwara K, McAlpine JN, Lheureux S, Matsumura N, Oza AM. Paradigm shift in the management strategy for epithelial ovarian cancer. Am Soc Clin Oncol Educ Book. 2016;35:e247-57. PMID: 27249730

Altman AD, Ferguson SE, Atenafu EG, Kobel M, McAlpine JN, Panzarella T, Lau S, Gien LT, Gilks B, Clarke B, Cameron A, Nelson G, Han G, Samouelian V, Ho TC, Louie K, Bernardini MQ. Canadian high risk endometrial cancer (CHREC) consortium: Analyzing the clinical behavior of high risk endometrial cancers. Gynecol Oncol. 2015 Nov 30;139(2):268-74. PMID: 26352641

Hoang LN, Zachara S, Soma A, Köbel M, Lee CH, McAlpine JN, Huntsman D, Thomson T, van Niekerk D, Singh N, Gilks CB. Diagnosis of ovarian carcinoma histotype based on limited sampling: a prospective study comparing cytology, frozen section, and core biopsies to full pathologic examination. Int J Gynecol Pathol. 2015 Nov 1;34(6):517-27. PMID: 26107565

Hanley GE, McAlpine JN, Kwon JS, Mitchell G. Opportunistic salpingectomy for ovarian cancer prevention. Gynecol Oncol Res Pract. 2015 Sep 17;2(1):1. PMID: 27231565

Hoang LN, McConechy MK, Kobel M, Anglesio M, Senz J, Maassen M, Kommoss S, Meng B, Postovit L, Kelemen LE, Staebler A, Brucker S, Kramer B, McAlpine JN, Gilks CB, Huntsman DG, Lee CH. Polymerase epsilon exonuclease domain mutations in ovarian endometrioid carcinoma. Int J Gynecol Cancer. 2015 Sep 1;25(7):1187-93. PMID: 26166557

Burleigh A, Talhouk A, Gilks CB, McAlpine JN. Clinical and pathological characterization of endometrial cancer in young women: identification of a cohort without classical risk factors. Gynecol Oncol. 2015 Jul 31;138(1):141-6. PMID: 25870916

Nelson BH, McAlpine JN. The more tumors change, the more they stay tame: Do T cells keep POLE ultramutated endometrial carcinomas in check? Gynecol Oncol. 2015 Jul;138(1):1. PMID: 26072691

Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015 Jul 14;113(2):299-310. PMID: 26172027

McConechy MK, Talhouk A, Li-Chang HH, Leung S, Huntsman DG, Gilks CB, McAlpine JN. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol. 2015 May 31;137(2):306-10. PMID: 25636458

Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakkum-Gamez J, McAlpine JN, Anglesio MS. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer. 2015 May 19;15(1):1. PMID: 25986173

McConechy MK, Hoang LN, Chui MH, Senz J, Yang W, Rozenberg N, Mackenzie R, McAlpine JN, Huntsman DG, Clarke BA, Gilks CB, Lee CH. In-depth molecular profiling of the biphasic components of uterine carcinosarcomas. J Clin Pathol Res. 2015 Apr 9;1(3):173-85. PMID: 27499902

Pearce CL, Stram DO, Ness RB, Stram DA, Roman LD, Templeman C, Menon U, Fasching PA, Doherty JA, Modugno F, Schildkraut JM, Rossing MA, McAlpine JN, Huntsman D, Wu AH, Berchuck A, Pike MC, Pharoah PDP. Population distribution of lifetime risk of ovarian cancer in the United States Cancer Epidemiol Biomarkers Prev. 2015 Apr 1;24(4):671-6. PMID: 25623732

Kwon JS, McAlpine JN, Hanley G, Finlayson S, Cohen T, Miller DM, Gilks CB, Huntsman DG. Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Obstet Gynecol. 2015 Feb 1;125(2):338-45. PMID: 25568991

Tone A, McConechy M, Yang W, Ding J, Yip S, Kong E, Wong K-K, Gershenson D, Mackay H, Shah S, Gilks CB, Tinker A, McAlpine JN, Clarke B, Huntsman D. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC Cancer 2014 Dec 18;14(1):982. PMID: 25523272

McAlpine JN, Greimel E, Brotto LA, Nout RA, Shash E, Avall-Lundqvist E, Friedlander ML, Joly F, on behalf of the Gynecologic Cancer Intergroup (GCIG). Quality of Life research in endometrial cancer: what is needed to advance progress in this disease site? Methodological considerations from the Gynecologic Cancer InterGroup Symptom Benefit Working Group brainstorming session, Leiden 2012. Int J Gynecol Cancer. 2014 Nov 1;24(9):1686-92. PMID: 25340293

Ha G, Roth A, Khattra J, Ho J, Yap D, Prentice LM, Melynk N, McPherson A, Bashashati A, Laks E, Biele J, Ding J, Le A, Rosner J, Shumansky K, Marra MA, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP. TITAN: Inference of copy number architectures in clonal cell populations from tumor whole genome sequence data. Genome Res. 2014 Nov 1;24(11):1881-93. PMID: 25060187

Gleicher N, McAlpine JN, Gilks CB, Kushnir VA, Lee HJ, Wu Y-G, Lazzaroni-Tealdi E, Barad DH. Absence of BRCA/FMR1 Correlations in Women with Ovarian Cancers. PLOS One 2014 Jul 18;9(7):e102370. PMID: 25036526

Joly F, McAlpine JN, Nout RA, Avall-Lundqvist E, Friedlander ML, on behalf of the Gynecologic Cancer Intergroup (GCIG). Quality of life and patient-reported outcomes in endometrial cancer clinical trials: a call for action! Int J Gynecol Cancer. 2014 Nov 1;24(9):1693-9. PMID: 25340294

Singh N, Leen SL, Han G, Faruqi A, Kokka F, Rosenthal A, Jiang J, Kim R, McAlpine JN, Gilks CB. Expanding the morphologic spectrum of differentiated VIN (dVIN) through detailed mapping of cases with p53 loss. Am J Surg Pathol. 2015 Jan 1;39(1):52-60. PMID: 25025443

Miller DM, McAlpine JN. Opportunistic salpingectomy for ovarian, fallopian tubal and peritoneal carcinoma risk reduction. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Last updated Aug 12, 2014.)

Lee, J-C, Liang C-W, Davidson B, Abeler VM, McAlpine J, Hoang LN, Huang H-N, Kuo K-T, Lin M-C, Lee C-H. MDM2 amplification is a frequent genetic aberration in Mullerian adenosarcomas. Modern Pathology (In Press).

McAlpine JN, Lisonkova S, Joseph KS, McComb P. Pelvic inflammation and the pathogenesis of ovarian cancer: a cohort study. Int J Gynecol Cancer. 2014 Oct;24 (8):140613. PMID:25191876.

Teng FF, Kalloger SE, Brotto, LA, McAlpine JN. Determinants of quality of life in ovarian cancer survivors: A pilot study. J Obstet Gynaecol Can, 2014 Aug;36(8):708-15. PMID:25222166.

McAlpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton KD, Gilks CB, Finlayson SJ, Hunstman DG, Miller DM; British Columbia’s Ovarian Cancer Research Program (OVARE). Opportunistic salpingectomy: uptake, risks and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014 May;210(5):471.e1-11.PMID: 24412119

Read CJ, McVey RM, Tone AA, Finlayson SJ, McAlpine JN, Fung-Kee-Fung M, Ferguson SE. The fallopian tube as the origin of high-grade serous ovarian cancer: review of a paradigm shift.  J Obstet Gynaecol Can 2014 Feb;36(2):133-40. PMID: 24518912

Bernard B, Clarke BA, Malowany JI, McAlpine J, Lee CH, Atenafu EG, Ferguson S, Mackay H. Uterine adenosarcoma: a dual-institution update on staging, prognosis and survival. Gynecol Oncol 2013 Dec; 131 (3): 634-9. PMID: 24135678.

Reade CJ, Finlayson S, McAlpine J, Tone AA, Fung-Kee-Fung M, Ferguson SE. Risk-reducing salpingectomy in Canada: a survey of obstetrician-gynaecologists. J Obstet Gynaecol Can 2013 Jul;35(7):627-34. PMID: 23876640

Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, Yang W, McConechy M, Melnyk N, Anglesio M, Luk MT, Tse K, Zeng T, Moore R, Zhao Y, Marra MA, Gilks B, Yip S, Huntsman DG, McAlpine JN, Shah SP. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.J Pathol. 2013 Sep;231(1):21-34. PMID: 23780408

McConechy MK, Ding J, Senz J, Yang W, Melynk N, Tone AA, Prentice LM, Wiegand KC, McAlpine JN, Shah SP, Lee CH, Goodfellow PJ, Gilks CB, Huntsman DG. Ovarian and endometrial endometroid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol. 2014 Jan;27(1):128-34. PMID: 23765252.

Friedlander ML, Stockler MR, Butow P, King MT, McAlpine J, Tinker A, Ledermann JA. Clinical trials of palliative chemotherapy in platinum-resistant or –refractory ovarian cancer: time to think differently?  J Clin Oncol 2013 Jun;31(18):2362. PMID: 23669225

Miller DM, McAlpine JN, Gilks CB, Huntsman DG. Opportunistic salpingectomy: the way forward-response to Steven Narod. Curr Oncol 2013 Jun;20(3):143-4. PMID: 23737680

Hoang LN, McConechy MK, Kobel M, Han G, Rouzbahman M, McAlpine JN, Davidson B, Irving J, Ali RH, Leung S, Liva E, Nucci O, Soslow RA, Huntsman DG, Gilks CB, Lee CH. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am J Surgical Path 2013 Sep;37(9):1421-32. PMID: 24076778

Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.Obstet Gynecol 2013 Jan;121(1):14-24. PMID: 23232752

Beirne JP, Quinn JE, Maxwell P, Kalloger SE, McAlpine J, Gilks CB, Harley IJ, McCluggage WG. BRCA1 immunohistochemical staining as a prognostic indicator in uterine serous carcinoma. Int J Gynecol Cancer 2013 Jan;23(1):113-118. PMID: 23221734

Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, Damaraju S, Fereday S, Winterhoff B, Kalloger SE, Senz J, Yang W, Steed H, Ferguson S, Teoman A, Allo G Garcia J, Schoolmeester JK, Shaw P, Bakkum-Gamez J, Tinker A, Bowtell D, Huntsman DG, Gilks CB, McAlpine JN. Molecular characterization of mucinous ovarian tumors supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.  J Pathology. 2013 Jan;229(1):111-20. PMID: 22899400

Le Page C, Kobel M, Ladurantage M, Rashimi K, Madore J, Babinszky S, Bachvarov D, Bartlett J, Beauchamp MC, Cass CE, Chadwick D, Crane C, Damarju S, Dufour J, Gotlieb WH, Kalloger SE, Portelance L, McAlpine JN, Matte I, Piche A, Shaw P, Vanderhyden BC, Watson PH, Huntsman DG, Provencher DM, Mes-Masson AM. Report on a molecular quality control exercise performed on specimens from Canadian biobanks partticipating in the COEUR specimen repository.Biopreservation and Biobanking. 2013.11 (2):83-93.

Tone A, McAlpine JN, Finlayson S, Gilks CB, Heywood M, Huntsman DG, Miller DM. It sounded like a good idea at the time. J Obstet Gynaecol Canada. 2012 Dec34(12):1127-32. PMID 23231793.

Schrader I, Hurlburt J, Gilks CB, Huntsman DG, McAlpine JN. Germline mutations in BRCA1 and BRCA2 in ovarian cancer: utility of a histology-based referral strategy. Obstetrics and Gynecology 2012 Aug;120 (2 Pt 1):235-40.

McConechy MK, Ding J, Cheang M, Wiegand K, Senz J, Tone A, Yang W, Prentice L, McAlpine JN Hirst M, Shah S, Lee C, Goodfellow PJ, Gilks CB, Huntsman DG. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathology 2012 Sep;228(1):20-30.

Tone A, Salvador S, Finlayson SJ, MD, Tinker AV, Kwon JS, Lee C, Cohen T, Ehlen T, Lee M, Carey MS, Heywood M, Pike J,Hoskins P, Stuart GC, Swenerton KD,Huntsman DG, Gilks CB, Miller DM, McAlpine, JN. The Role of the Fallopian Tube in Ovarian Cancer. Clinical Advances in Hematologic Oncology 2012 May;10(5):296-306.

McAlpine JN, Porter H, Kalloger SE, Senz, J, Kalloger SE, Nelson B, Prentice L, Ding J, Milne K, Shah SP, Huntsman DG, Gilks CB. BRCA1/2 mutations are only associated with high grade serous subtype of ovarian cancer and correlate with p53 abnormalities and the presence of immune cell infiltrates. Modern Pathology, 2012 May;25(5):740-50.

Brotto, L, Erskine Y, Carey M, Ehlen T, Finlayson S, Heywood M, Kwon J, Thomson S, Stuart G, McAlpine JN, Miller DM. A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. Gynecologic Oncology, 2012 May;125(2):320-5.

Brotto L, Branco N, Dunkley C, McCullum M, McAlpine JN. Bilateral salpingo-oophorectomy and sexual health: A mixed methods study exploring risk-reducing versus benign surgery groups. Journal of Obstetrics and Gynaecology Canada, 2012 Feb;34(2):172-8.

Lee CH, Chiang S, McAlpine JN, Huntsman DG, Gilks CB, Fletcher J. 14-3-3 fusion oncogenes in endometrial cancer. Proceedings of National Academy of Science, 2012 Jan;109(3):929-34.

 


For a full list of publications please contact the Dr. McAlpine directly.

Grants

Canadian Research Society (CRS). Circulating tumour DNA mutations in endometrial and ovarian cancer patients can be used to guide clinical management. PI: McAlpine JN. Co-applicants: Huntsman DG, Gilks CB, Shah SP (2015-2017). $119,147. AWARDED 09/14

Canadian Cancer Society Research Institute (CCSRI). A Population-based assessment of an ovarian cancer prevention program. PI: Huntsman D, McAlpine J. Co-applicants: Coldman A, Gilks B, Miller D, Mitchell G. (2014-2017) $162,307. AWARDED 08/14

Terry Fox Research Institute. Genomics of Frome Fruste Tumours: New Vistas on Cancer Biology and Treatment. Nom PI: Huntsman D. PI: Aparicio S, Hansen C, Hirst M, Lee C-H, Marra M, Morin G, Nielsen T, Shah S, Sorensen P, Underhill TM, Yip S. Co-applicants: Tinker A, McAlpine J, Clarkson P, Schaeffer D. (2014-2019) $7,500,000. AWARDED 07/13

BC Cancer Foundation (BCCF) Sarabjit Gill Memorial Fund, Understanding intra-tumoral heterogeneity within endometrial cancers. Principal Applicant: McAlpine JN (2013-2015). $80,000 AWARDED 07/13

BC Cancer Foundation (BCCF) Funded Project, SMART Cancer Project: Shared Access Medicine an Approach to Rare Tumors Co-Principal Applicants: McAlpine JN and Tinker A. (2013-2016). $264,100 AWARDED 7/13.

Canadian Cancer Society Research Institute (CCSRI) Impact Grant. Contextual genomics: The foundation for subtype specific approaches to ovarian cancer control. PI: Huntsman D. Co-Applicants: Miller D, Morin R, Shah S, McAlpine J, Carey M, Cullis P, Hoskins P, Yong P, Gilks B, Tinker A. (2013-2018) $1,996,690 AWARDED 2/13

Canadian Institute of Health Research (CIHR). PrOTYPE: An Enabling Techology to Imporve Ovarian Cancer Care. PI: Huntsman, DG. Co-Applicants: Anglesio M, McAlpine JN. $159,985. AWARDED 1/13

Physiotherapy Foundation of Canada. Pelvic floor muscle exercises for urinary incontinence in gynecological cancer survivors. Campbell KL. McAlpine J, Brotto L, Finlayson S, Wilson P, Lieblich P, Sran M, Dayan M. Physiotherapy Foundation of Canada, $4000 AWARDED 6/12

Terry Fox Research Institute. Seed/pilot funding for the SMART initiative: Shared Access Medicine for Rare Tumors. PI’s: Tinker A, McAlpine JN, Huntsman DG. $25K/1 year. AWARDED 12/11.

British Columbia Ovarian Cancer Research (OvCaRe) and Carraresi Foundation. High grade serous carcinomas with ovarian and endometrial involvement: characterization, determination of site of origin, and a step towards a better classification system. PI: McAlpine JN, Co-Applicant: Gilks CB. ~9K/2 year. AWARDED 1/12.

British Columbia Ovarian Cancer Research (OvCaRe) and Carraresi Foundation Salpingectomy for risk reduction in BRCA1/2 mutation carriers: a cost analysis. PI: Kwon J, Co-Applicant: McAlpine JN. ~12K/2 year. AWARDED 1/12.

CIHR Operating Grant March 2011. Genomic Disruption in High-Grade Serous Ovarian Carcinomas: Steady State or Continuous Drift? PI’s: Shah SP, McAlpine JN. $563,330/4 years. AWARDED 6/11.

Martha Piper Research Fund: Selective Excitation Light Fluorescence (SELF) Imaging In Vivo PI: Calum MacAulay Co-Applicant McAlpine JN $23,450. AWARDED 04/11.

Genzyme Biosurgery (Investigator Initiated Research Grant). Seprafilm™ for the prevention of intraperitoneal adhesions and improved delivery of therapy in women undergoing surgical staging and intraperitoneal chemotherapy for advanced ovarian cancer. PI: McAlpine ~$22,000 ($40,000 minus product). AWARDED 4/09. Closed Dec 2013.

Ovarian Cancer Canada. Pilot project funding. Ovarian Cancer Early Screening Project (OCESP): Lower genital tract secretions for early screening of pelvic epithelial cancers. PI: J.N. McAlpine JN $30,000 AWARDED 6/08 (completed)

Merck (US-Investigator Initiated Research Grant). The Impact of Bisphosphonates on bone loss in patients undergoing surgery and postoperative chemotherapy for gynecologic malignancies.
PI: McAlpine JN 2005 USA and awarded in Canada 5/08, ~$32,000 (closed)

Canadian Institutes of Health Research (CIHR). A Study of the Immunobiology of an HPV VLP Vaccine in a Cohort of HIV Positive Girls and Women. PI: Money D.Collaborator: McAlpine JN. ~$1,389,043 over 5 years. AWARDED 3/08.

SALARY AWARDS

CIHR New Investigator Award. Genomic Disruption in High-Grade Serous Ovarian Carcinomas: Steady State or Continuous Drift? McAlpine JN $60,000/year x5 years. AWARDED 6/12.

Vancouver Coastal Health Research Institute In it For Life Mentored Clinical Scientist Award, 2008. PARP inhibitors in epithelial ovarian cancer: targeted molecular therapy in BRCA null phenotypes and mechanisms of resistance. PI: J.N. McAlpine $50,000/year (granted 3 years). AWARDED 6/08.